Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04895358 |
|---|---|
| Brief Title: | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) |
| First Submitted : | May 17, 2021 |
| First Submitted that Met QC Criteria : | May 17, 2021 |
| First Posted : | May 20, 2021 |
| Last Update Submitted that Met QC Criteria : | August 11, 2022 |
| Last Update Posted : | August 12, 2022 (Estimate) |